Ossium Health

What Ossium Health does

Ossium Health, Inc. is a San Francisco-based, privately held clinical-stage bioengineering company founded in 2016 that has built what it describes as the first deceased-donor bone marrow banking platform. The company recovers vertebral body bone marrow from deceased organ donors through partnerships with Organ Procurement Organizations such as Legacy of Life Hawaii, then processes and cryopreserves the tissue in a ~34,000 square foot Indianapolis manufacturing facility containing five ISO 7 cleanrooms. From this platform Ossium produces HPC, Marrow (cryopreserved whole bone marrow for allogeneic hematopoietic stem cell transplantation), OssiGraft and OssiGraft Prime viable bone matrix allografts for orthopedic and spine surgery, GMP and research-use-only mesenchymal stem cells (vBM MSCs), and GMP and research-use-only CD34+ hematopoietic stem cells, the latter two supported by an FDA Master File and available with reference letters for IND filings. Ossium reports greater than 100% increase in cell yield per donor versus standard methods, 24-hour HLA matching, and 72-hour shipment for off-the-shelf bone marrow grafts.

The company sells its clinical products on a quote-based, sales-led motion through Medical/Scientific Liaison teams and Regional Sales Directors to transplant centers, hematologists, and orthopedic surgeons. Distribution is supplemented by the HOPE Expanded Access Program (NCT07145411), which ships cryopreserved HPC, Marrow within three days of request for patients with urgent unmet transplant needs, and by clinical trial enrollment through PRESERVE I (NCT05589896), a Phase 2 study of HLA-partially matched deceased donor bone marrow for hematologic malignancies. An ongoing partnership with the US Biomedical Advanced Research and Development Authority (BARDA) extends the HPC, Marrow platform into radiological/nuclear emergency preparedness. Revenue derives from clinical and RUO product sales plus non-dilutive grant and contract funding (CIRM, BARDA), with the company preparing for full-scale commercial launch under a newly appointed Chief Commercial Officer.

Ossium has raised approximately $125 million in venture funding (Series A $10M in 2018, Series B $63M in 2020, Series C $52M in 2023) from investors including CPMG, Vivo Capital, General Catalyst, First Round Capital, Manta Ray Ventures, Alumni Ventures, Asahi Kasei, Village Global, and XYZ Capital. The company holds FDA Tissue Establishment Registration, CLIA accreditation, AATB accreditation, COLA accreditation, and tissue bank registrations in California, Delaware, Illinois, Maryland, New York, and Oregon. As of April 2026, 23 patients had received transplants using Ossium-processed deceased-donor bone marrow.

Name

Ossium Health

Legal name

Ossium Health, Inc.

Website

https://ossiumhealth.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Ossium Health operates a deceased-donor bone marrow banking platform that recovers, processes, and cryopreserves vertebral body tissue into HPC, Marrow, OssiGraft viable bone allografts, and GMP/RUO MSCs and CD34+ cells for transplant centers, orthopedic surgeons, and cell therapy researchers.

Ownership category

akta.pro rank

Product category

Cell therapy products and bone marrow banking

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Dental Laboratories (339116), Blood and Organ Banks (621991)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Bone marrow banking
• Cell therapy products
• Hematopoietic cell transplantation
• Viable bone allografts
• Mesenchymal stem cells

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D

Revenue model

1. Clinical cell therapy and allograft product sales: Sale of manufactured clinical products — HPC, Marrow; GMP CD34+; GMP MSCs; and OssiGraft viable bone matrix allografts — to transplant centers, orthopedic surgeons, and research institutions. Sold under HOPE expanded access and standard product catalog.
2. Research Use Only (RUO) MSC sales: Sale of RUO-grade MSCs for academic and industry research and development purposes.
3. Government grant funding (BARDA, CIRM): Non-dilutive and contract funding from the US Biomedical Advanced Research and Development Authority (BARDA) to advance HPC, Marrow for radiological/nuclear emergency preparedness, and a $3.46M grant from the California Institute for Regenerative Medicine (CIRM).

Pricing tiers

Go-to-market motion5 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ossium Health operates a deceased-donor bone marrow banking platform that recovers bone marrow from organ donor vertebral bodies through partnerships with Organ Procurement Organizations, then processes and cryopreserves it under GMP conditions for distribution as off-the-shelf cell therapy products. The company manufactures and sells HPC, Marrow (cryopreserved hematopoietic progenitor cells) for allogeneic hematopoietic stem cell transplantation, OssiGraft and OssiGraft Prime viable bone matrix allografts for orthopedic and spine surgery, plus GMP and RUO grade mesenchymal stem cells and selected CD34+ cells for clinical and research use.

Product overview

Ossium Health operates a platform-plus-modules architecture centered on its proprietary organ donor bone marrow banking platform, which recovers bone marrow from deceased organ donor vertebral bodies, processes and cryopreserves it in state-of-the-art ISO 7 cleanrooms, and distributes it for clinical and research use. The core hematologic product, HPC, Marrow, is supplemented by the orthopedics module OssiGraft™ (with its next-generation variant OssiGraft Prime™) for musculoskeletal defects, a clinical pipeline (PRESERVE I Phase 2 study for hematologic malignancies and the OSSM-007 program for steroid-refractory acute GVHD), and a parallel GMP and RUO cell-products portfolio covering GMP Mesenchymal Stem Cells (vBM MSCs), GMP Selected CD34+ Cells, and their research-use-only counterparts (RUO MSCs and RUO Selected CD34+ Cells). The HOPE Expanded Access Program operationalizes HPC, Marrow delivery for urgent or unmet transplant needs, shipping cryopreserved grafts within 3 days of request.

Differentiator

Problem solved

Functional benefit

Brands

• OssiGraft™: Viable bone matrix allograft containing a formulation of cryopreserved cells in their native bone niche, intended for the repair, replacement, and reconstruction of musculoskeletal defects of the spine, pelvis, or extremities.
• OssiGraft Prime™
• HPC, Marrow
• CHIMERA
• INVENTA
• CHYMALIS
• ENGINEERING LIFE
• THE GREATEST WEALTH IS HEALTH
• HEALTH IS WEALTH

Products and services

• HPC, Marrow Cryopreserved whole bone marrow derived from organ donor vertebral bodies using Ossium's proprietary processing methods, containing Hematopoietic Progenitor Cells (HPCs). Designed as an off-the-shelf graft source for allogeneic hematopoietic stem cell transplantation, targeting acute leukemias and other hematologic malignancies, with 24-hour HLA matching and 72-hour shipment availability.
• OssiGraft Cryopreserved viable bone matrix allograft containing viable cryopreserved cells in their native bone niche. Available in a variety of sizes and intended for repair, replacement, and reconstruction of musculoskeletal defects of the spine, pelvis, or extremities. Median donor age 35 years, average tissue recovery time 4.5 hours, thaw time ≤5 minutes, 100% tissue purity, 70-80% cancellous bone composition. Regulated by FDA under section 361 of the PHS Act and 21 CFR Part 1271.
• OssiGraft Prime Premium cryopreserved viable bone matrix allograft and next-generation version of OssiGraft, engineered with innovative processing advancements for orthopedic and spine surgeons. Available in a variety of sizes for repair, replacement, and reconstruction of musculoskeletal defects of the spine, pelvis, or extremities. Regulated under section 361 of the PHS Act and 21 CFR Part 1271.
• GMP Human Mesenchymal Stem Cells (vBM MSCs) GMP cryopreserved mesenchymal stem cells derived from vertebral bodies of organ donors (SKU INVC-006-100, 100 million cells/vial, Passage 4). Express typical MSC markers (CD73, CD90, CD105), lack hematopoietic and HLA class II markers, with per-donor cell populations two to three orders of magnitude higher than traditional BM-MSCs. Suitable for use in IND-approved clinical studies.
• GMP Selected CD34+ Cells GMP-grade CD34+ cells aseptically selected from vertebral body bone marrow by density gradient and positive immunomagnetic separation (SKU INVC-005-25, 25 million cells/vial). Analyzed for purity and viability by flow cytometry with post-thaw viability at or above 95%. Packaged in CryoStor CS10 cryoprotectant. Suitable for use in IND-approved clinical studies.
• RUO Mesenchymal Stem Cells Research-use-only cryopreserved MSCs derived from the vertebral bodies of organ donors, phenotypically and functionally equivalent to MSCs obtained from aspirated bone marrow. Available in Passage 2 (SKU INVR-001-1) and Passage 4 (SKU INVR-002-1) at 1 million cells/vial. Express typical MSC surface markers (CD73, CD90, CD105), lack hematopoietic and HLA class II markers, and undergo trilineage differentiation.
• RUO Human Selected CD34+ Stem Cells Research-use-only human CD34+ cells, positively selected from HPC, Marrow and enriched for hematopoietic stem cells, aseptically selected from vertebral body bone marrow by density gradient and positive immunomagnetic separation. Available in 500,000 cell (INVR-003-0.5), 1 million cell (INVR-003-1), and 2 million cell (INVR-003-2) vial sizes.
• HOPE Expanded Access Program (HPC, Marrow) Expanded Access Program providing cryopreserved HPC, Marrow to patients with urgent or unmet allogeneic bone marrow transplant needs, with grafts shipped within 3 days of request. Covers clinical scenarios including primary/secondary graft failure, additional chemotherapy cycles not preferred, living donor falling through after conditioning, high-risk MDS/AML, rare HLA types, severe aplastic anemia, refractory AML requiring rescue immune system, and partial-remission-but-eligible patients. Listed on ClinicalTrials.gov as NCT07145411.

Quantifiable outcome

• Greater than 100% increase in cell yield per donor
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered flagship government partner, top recovery partner, awareness partner, major public partner and flagship clinical site.

• Biomedical Advanced Research and Development Authority (BARDA)flagship government partnerStrategic or Co-development Partner · 1 April 2023BARDA partnership to advance the use of HPC, Marrow for radiological and nuclear emergencies, providing non-dilutive funding for Ossium's preparedness program.
• Legacy of Life Hawaiitop recovery partnerChannel Partner/ Reseller/ DistributorRecognized as Ossium's Top Recovery Partner 2025; an OPO that recovers deceased donor bone marrow (vertebral bodies) for Ossium's processing platform.
• Donate Lifeawareness partnerGTM or Marketing PartnerDonate Life is referenced as a partner on the Partners page, supporting donation awareness and community engagement alongside Ossium.
• State of Indianamajor public partnerStrategic or Co-development PartnerPublic partnership with the State of Indiana, announced with the Governor of Indiana, supporting the establishment of Ossium's Indianapolis processing facility.
• Henry Ford Healthflagship clinical siteStrategic or Co-development PartnerHenry Ford Health treated the first leukemia patient using Ossium's bone marrow product through the HOPE program; serves as a clinical partner for ongoing HOPE expanded access.
• Columbia University Medical Centerflagship clinical siteStrategic or Co-development PartnerColumbia University Medical Center treated the first patient with Ossium's GMP CD34+ product, serving as an early clinical partner for the CD34+ platform.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• LifeNet Health: Non-profit tissue bank that recovers, processes, and distributes allograft and cell-based products (including viable bone matrices) from deceased donors, mirroring Ossium's deceased-donor recovery and processing model and competing in orthopedics and spine allografts.
• MTF Biologics: Tissue bank and regenerative medicine organization offering allograft and cell-based orthopedic and wound care products from deceased donors, directly comparable to Ossium's OssiGraft viable bone matrix product line and OPO-style recovery partnerships.
• Gamida Cell: Clinical-stage cell therapy company developing omidubicel (an ex vivo expanded cord blood-derived graft) for allogeneic hematopoietic stem cell transplantation in hematologic malignancies, directly competing with Ossium's HPC, Marrow for the same alloHCT patient pool.
• Mesoblast: Commercial-stage cell therapy company selling remestemcel-L (an allogeneic bone marrow-derived mesenchymal stem cell product) for steroid-refractory acute GVHD, directly overlapping Ossium's MSC and OSSM-007 GVHD pipeline and sharing a bone-marrow-derived MSC platform.

Emerging players

• Cellerant Therapeutics: Clinical-stage cell therapy and antibody developer focused on hematologic indications including acute radiation syndrome, a therapeutic area that overlaps with Ossium's BARDA-funded HPC, Marrow program for radiological/nuclear emergencies.
• Pluristem Therapeutics: Cell therapy company developing placenta-derived allogeneic cell therapies for hematologic and orthopedic indications; shares Ossium's allogeneic, off-the-shelf cell therapy positioning and the GVHD/orthopedic pipeline overlap.

Broad incumbents

• Allogene Therapeutics: Allogeneic CAR-T cell therapy leader with a broader oncology portfolio; competes for the same hematologic malignancy patients that Ossium's HPC, Marrow targets via bone marrow transplant, and represents the long-term engineered-cell-therapy threat to conventional alloHCT grafts.
• Cryo-Cell International: Public cord blood and menstrual stem cell banking company; competes as an alternative cryopreserved cell source for transplantation and family banking, addressing the same donor-shortage problem Ossium targets but with a different (umbilical cord) supply model.
• Vertex Pharmaceuticals (CTX001 / CASGEVY program with CRISPR Therapeutics): Commercial-stage gene-edited ex vivo cell therapy (Casgevy) for sickle cell disease and beta-thalassemia; a leading example of the engineered cell therapy modality that could ultimately substitute for Ossium's deceased-donor bone marrow graft approach in hematologic diseases.
• CBR (Cord Blood Registry) / Generate Life Sciences: Largest US cord blood bank offering family and public cord blood banking, providing an alternative cryopreserved hematopoietic stem cell source that overlaps with Ossium's HPC, Marrow value proposition for transplant-eligible patients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ossiumhealth
• LinkedInlinkedin.com/company/ossium-health
• Facebookfacebook.com/ossiumhealth

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ossium Health